0001179110-21-010165.txt : 20211116 0001179110-21-010165.hdr.sgml : 20211116 20211116160233 ACCESSION NUMBER: 0001179110-21-010165 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211112 FILED AS OF DATE: 20211116 DATE AS OF CHANGE: 20211116 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Young Diane C. CENTRAL INDEX KEY: 0001648010 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15006 FILM NUMBER: 211416010 MAIL ADDRESS: STREET 1: 175 TOYOTA PLAZA, 7TH FLOOR CITY: MEMPHIS STATE: TN ZIP: 38103 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Celldex Therapeutics, Inc. CENTRAL INDEX KEY: 0000744218 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133191702 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 BUSINESS PHONE: 908-200-7500 MAIL ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 FORMER COMPANY: FORMER CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC DATE OF NAME CHANGE: 19980828 FORMER COMPANY: FORMER CONFORMED NAME: T CELL SCIENCES INC DATE OF NAME CHANGE: 19920703 4 1 edgar.xml FORM 4 - X0306 4 2021-11-12 0 0000744218 Celldex Therapeutics, Inc. CLDX 0001648010 Young Diane C. C/O CELLDEX THERAPEUTICS, INC. 53 FRONTAGE ROAD, SUITE 220 HAMPTON NJ 08827 0 1 0 0 SVP, Chief Medical Officer Common Stock 2021-11-12 4 M 0 4600 10.38 A 6715 D Common Stock 2021-11-12 4 S 0 4600 42.9411 D 2115 D Incentive Stock Option (Right to Buy) 10.38 2021-11-12 4 M 0 4600 0.00 D 2030-06-18 Common Stock 4600 67400 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.6400 to $43.2000 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. /s/ Sam Martin, attorney-in-fact for Diane C. Young 2021-11-16